<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821233</url>
  </required_header>
  <id_info>
    <org_study_id>ZWI-ZW49-101</org_study_id>
    <nct_id>NCT03821233</nct_id>
  </id_info>
  <brief_title>A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers</brief_title>
  <official_title>A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zymeworks Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zymeworks Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to&#xD;
      establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the&#xD;
      investigational agent under study, and to assess the safety and tolerability of ZW49.&#xD;
      Eligible patients include those with locally advanced (unresectable) or metastatic&#xD;
      HER2-expressing cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will use a 3+3 dose-escalation study design to evaluate the safety and tolerability&#xD;
      of ZW49 and to determine the MTD or RD of ZW49 for further study. Selected expansion cohorts&#xD;
      will be subsequently opened based upon Safety Monitoring Committee (SMC) recommendation and&#xD;
      sponsor approval to further evaluate the safety and tolerability of ZW49 at the MTD or RD and&#xD;
      to assess preliminary anti-tumor activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Number of participants who experienced a DLT. DLTs are events that occur following administration of any amount of ZW49 and are considered related to ZW49 per the investigator. DLTs will include only events considered related to ZW49.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Number of participants who experienced an adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of lab abnormalities</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology and chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of electrocardiogram (ECG) and left ventricular ejection fraction (LVEF) abnormalities</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Number of participants who experienced an abnormal ECG or LVEF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose reductions of ZW49</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Number of doses reduced and number of participants who require a dose reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ZW49</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>End of infusion concentration, maximum serum concentration, and trough concentration of ZW49</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs)</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Number of participants who develop ADAs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of participants who achieved a best response of either complete or partial response during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of participants who achieved a best response of complete response, partial response, or stable disease during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median duration of response (in months) and range (minimum, maximum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median progression-free survival (in months) and range (minimum, maximum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median overall survival (in months) and range (minimum, maximum)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>HER2-expressing Cancers</condition>
  <arm_group>
    <arm_group_label>ZW49</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZW49</intervention_name>
    <description>Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC&#xD;
Expansion: MTD or RD identified in the dose-escalation part of the study</description>
    <arm_group_label>ZW49</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically-confirmed diagnosis of breast cancer, gastroesophageal adenocarcinoma&#xD;
             (GEA), or other HER2-expressing cancer with evidence of locally advanced&#xD;
             (unresectable) and/or metastatic disease.&#xD;
&#xD;
               -  Dose-escalation (Cohort 1): HER2-high advanced solid tumors&#xD;
&#xD;
               -  Expansion (Cohort 2): HER2-high breast cancer&#xD;
&#xD;
               -  Expansion (Cohort 3): HER2-high GEA&#xD;
&#xD;
               -  Expansion (Cohort 4): HER2-high other non-breast and non-GEA cancers&#xD;
&#xD;
          -  Progressive disease that has progressed on or been refractory to all standard of care.&#xD;
             Patients who were intolerant to or ineligible for standard therapy may be eligible if&#xD;
             the reasons are carefully documented and approval is provided by the sponsor medical&#xD;
             monitor&#xD;
&#xD;
               -  Patients with HER2-high breast cancer must have received prior treatment with&#xD;
                  trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1)&#xD;
&#xD;
               -  Patients with HER2-high GEA must have received prior treatment with trastuzumab&#xD;
&#xD;
          -  Sites of disease assessible per Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             version 1.1&#xD;
&#xD;
               -  Dose-escalation: measurable or non-measurable disease&#xD;
&#xD;
               -  Expansion: measurable disease&#xD;
&#xD;
          -  ECOG performance status score of 0 or 1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Adequate cardiac left ventricular function, as defined by a LVEF &gt;/= institutional&#xD;
             standard of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of myocardial infarction or unstable angina within 6 months prior to&#xD;
             enrollment, troponin levels consistent with myocardial infarction, or clinically&#xD;
             significant cardiac disease, such as ventricular arrhythmia requiring therapy,&#xD;
             uncontrolled hypertension, or any history of symptomatic congestive heart failure&#xD;
             (CHF)&#xD;
&#xD;
          -  Clinically significant infiltrative pulmonary disease not related to lung metastases&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection or other known chronic liver disease&#xD;
&#xD;
          -  Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with&#xD;
             exception of patients with Gilbert's Syndrome, asymptomatic gall stones, liver&#xD;
             metastases, or stable chronic liver disease per investigator assessment)&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Brain metastases: Untreated CNS metastases, symptomatic CNS metastases, or radiation&#xD;
             treatment for CNS metastases within 4 weeks of start of study treatment. Stable,&#xD;
             treated brain metastases are allowed (defined as patients who are off steroids and&#xD;
             anticonvulsants and are stable for at least 1 month at the time of screening).&#xD;
&#xD;
          -  Known leptomeningeal disease (LMD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Woolery, PharmD, BCOP</last_name>
    <role>Study Director</role>
    <affiliation>Zymeworks Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zymeworks Clinical Trial Resource</last_name>
    <phone>(206) 237-1030</phone>
    <email>medinfo@zymeworks.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yan Xing, MD, MS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Pegram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Heather Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Catenacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Komal Jhaveri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rishi Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anthony Tolcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christos Karapetis, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Bedard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cristiano Ferrario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Keun-Wook Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yeul Hong Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Do-Youn Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>Biparatopic antibody</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Gastric cancers</keyword>
  <keyword>Esophageal cancers</keyword>
  <keyword>Gastroesophageal junction (GEJ) cancers</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

